Open Access

Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report

  • Authors:
    • Xin Zhou
    • Shi-Ting Huang
    • Ning-Ning Shan
  • View Affiliations

  • Published online on: June 24, 2025     https://doi.org/10.3892/ol.2025.15156
  • Article Number: 410
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present report aims to improve the understanding of the clinicopathological features of chronic myeloid leukemia (CML) harboring concomitant T315I and E459K mutations. CML with the T315I mutation alone and in combination with other mutations has demonstrated sensitivity to olverembatinib, a third‑generation tyrosine kinase inhibitor, providing valuable insights into potential treatment strategies for this rare mutational profile. In the present study, a 57‑year‑old woman with a 7‑year history of CML relapsed 1 year after stopping imatinib treatment. The patient presented with right arm pain and bone lesions confirmed by imaging. Laboratory tests and bone marrow analysis confirmed CML in the chronic phase, and the patient initially responded well to dasatinib. After 5 months, severe pancytopenia developed. Next‑generation sequencing (NGS) revealed concomitant T315I and E459K mutations in the breakpoint cluster region‑Abelson tyrosine kinase 1 tyrosine kinase domain, as well as an ASXL transcriptional regulator 1 mutation, indicating progression to the blast phase. Treatment was switched to olverembatinib, and allogeneic hematopoietic stem cell transplantation (allo‑HSCT) was recommended. Overall, patients with multiple mutations in CML tend to have a worse prognosis due to treatment resistance and disease progression. NGS is crucial for detecting low‑frequency mutations and allo‑HSCT also serves a key role in treating high‑risk cases.
View Figures
View References

Related Articles

Journal Cover

September-2025
Volume 30 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou X, Huang S and Shan N: Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report. Oncol Lett 30: 410, 2025.
APA
Zhou, X., Huang, S., & Shan, N. (2025). Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report. Oncology Letters, 30, 410. https://doi.org/10.3892/ol.2025.15156
MLA
Zhou, X., Huang, S., Shan, N."Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report". Oncology Letters 30.3 (2025): 410.
Chicago
Zhou, X., Huang, S., Shan, N."Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report". Oncology Letters 30, no. 3 (2025): 410. https://doi.org/10.3892/ol.2025.15156